Meeting
2023 ASCO Annual Meeting
An exploratory clinical trial on intra-lumbar injection of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas.
Authors
Xiaoyun Shang
T-MAXIMUM Pharmaceutical (Suzhou) Co., Ltd., Suzhou, China
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
ChiCTR2100047968
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2043)
DOI
10.1200/JCO.2023.41.16_suppl.2043
Abstract #
2043
Poster Bd #
400
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma.
First Author: Nader Sanai
Poster
2017 ASCO Annual Meeting
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
First Author: Alvaro Henrique Ingles Garces
Poster
2022 ASCO Annual Meeting
DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.
First Author: David A. Reardon
Poster
2022 ASCO Annual Meeting
Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.
First Author: Amit M. Oza